Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
Status:
Completed
Trial end date:
2014-06-13
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well giving spironolactone works in preventing
rash in patients with cancer that has spread to other places in the body and are receiving
panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor
(EGFR) inhibitor-induced skin rash.